Amgen amend GDNF gene permit agreement Amsterdam Molecular Therapeutics Holding N.

‘This agreement will allow us to progress the program for Parkinson’s Disease ahead and at exactly the same time find a partner who will support the financing of our GDNF programs in alternative indications. Expanding the partnering possibilities could mean sustained interest as the widened therapeutic applications present more chances of success, potentially much less complex product development paths and in many cases fewer patients to enroll in clinical trials.’.. AMT, Amgen amend GDNF gene permit agreement Amsterdam Molecular Therapeutics Holding N.V. , a head in the advancement of gene-based therapies, today announced that it has amended and restated its licensing agreement with Amgen for gene therapy applications incorporating the GDNF gene, to which Amgen keeps rights.KlegermanMelatonin and the circadian rhythm: an interview with Professor Kennaway, University of AdelaideThe researchers place the mice on a 12-hour light/dark cycle, and provided meals for four hours in the center of the light portion. Because mice feed at night normally, this pattern is comparable to human beings eating at inappropriate occasions. Dysfunctional eating patterns are likely involved in human obesity, in the nocturnal eating frequently seen in obese people particularly, the researchers be aware.